Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Jul;30(1):157–160. doi: 10.1128/aac.30.1.157

Penetration of cefuzoname into the cerebrospinal fluid of rabbits.

T Haruta, H Yamamoto, K E Okura, S Kuroki, Y Kobayashi
PMCID: PMC176455  PMID: 3530123

Abstract

Concentrations of cefuzoname in cerebrospinal fluid (CSF) were determined in a total of 16 rabbits, 5 with healthy meninges, 5 with Staphylococcus aureus meningitis, and 6 with Escherichia coli meningitis. Mean percentages of the maximum concentration of the drug in CSF versus that in serum were 0.57, 3.37, and 4.40% for healthy rabbits, those with staphylococcal meningitis, and those with E. coli meningitis, respectively. The percentages of the area under the concentration-time curve of cefuzoname in CSF versus that in serum were, in the order of healthy group, staphylococcal meningitis group, and E. coli meningitis group, 0.61, 4.99, and 8.04% at 15 to 60 min, 1.44, 7.09, and 12.7% at 15 to 120 min, and 1.87, 8.07, and 15.8% at 15 to 180 min after administration, showing significant differences between the healthy and meningitis groups. All of the values in the E. coli meningitis group were greater than those of the staphylococcal meningitis group, but the differences were not significant. The ratios of the half-life of cefuzoname in CSF to that in serum were 2.10, 1.98, and 3.37 for the healthy, staphylococcal meningitis, and E. coli meningitis groups, respectively, with no significant difference between the three groups. Cefuzoname seems to be among the middle ranks of beta-lactam agents as far as penetration rate is concerned; however, when its potent antibacterial activity and broad spectrum are taken into account, the concentrations in CSF in patients with meningitis seem worth examining.

Full text

PDF
157

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Deguchi K., Fukuyama S., Nishimura Y., Nishike A., Fukumoto T., Oda S., Sato S., Matsumoto Y., Ikegami R., Yokota N. [MICs and MBCs of cefotaxime, desacetylcefotaxime and ceftriaxone against four principal bacteria causing meningitis]. Jpn J Antibiot. 1984 Sep;37(9):1701–1713. [PubMed] [Google Scholar]
  2. Kobayashi Y., Haruta T., Kuroki S., Okura K. [Experimental and clinical studies on cefsulodin in the pediatric field]. Jpn J Antibiot. 1982 Nov;35(11):2713–2720. [PubMed] [Google Scholar]
  3. Kobayashi Y., Haruta T., Morikawa Y., Fujiwara T. [Trend of bacterial meningitis in children over a 13-year period (1966 through 1978) in Japan. An analysis based on studies in 127 institutions (author's transl)]. Jpn J Antibiot. 1979 Aug;32(8):795–805. [PubMed] [Google Scholar]
  4. Kobayashi Y., Haruta T., Okura K. Cerebrospinal fluid penetration after combined administration of cefotaxime and ampicillin to rabbits with staphylococcal meningitis. J Antimicrob Chemother. 1984 Sep;14 (Suppl B):125–134. doi: 10.1093/jac/14.suppl_b.125. [DOI] [PubMed] [Google Scholar]
  5. Kobayashi Y., Haruta T., Ookura K., Kuroki S., Tsutsui T. [Fundamental and clinical evaluations of cefmenoxime in the field of pediatrics]. Jpn J Antibiot. 1982 Nov;35(11):2555–2568. [PubMed] [Google Scholar]
  6. Kobayashi Y., Morikawa Y., Haruta T., Fujiwara T. [Experimental studies on the passage of CS-1170 into the cerebrospinal fluid (author's transl)]. Jpn J Antibiot. 1979 Jan;32(1):35–40. [PubMed] [Google Scholar]
  7. Kobayashi Y., Morikawa Y., Haruta T., Fujiwara T. [Experimental studies on the passage of cefamandole sodium into the cerebrospinal fluid (author's transl)]. Jpn J Antibiot. 1979 Sep;32(9):905–911. [PubMed] [Google Scholar]
  8. Kobayashi Y., Morikawa Y., Haruta T., Fujiwara T. [Fundamental and clinical studies on cefuroxime in children (author's transl)]. Jpn J Antibiot. 1979 Dec;32(12):1219–1229. [PubMed] [Google Scholar]
  9. Kobayashi Y., Morikawa Y., Haruta T., Kuroki S., Ohkura K., Fujiwara T. [Clinical evaluation of cefotiam in children (author's transl)]. Jpn J Antibiot. 1981 Jun;34(6):994–1001. [PubMed] [Google Scholar]
  10. Kobayashi Y., Morikawa Y., Haruta T., Ookura K., Kuroki S., Murakami M., Tomizawa T., Kikawa Y., Kasei M., Hayashi R. [Fundamental and clinica evaluation of cefoxitin in children (author's transl)]. Jpn J Antibiot. 1981 Mar;34(3):318–332. [PubMed] [Google Scholar]
  11. McCracken G. H., Jr Management of bacterial meningitis in infants and children. Current status and future prospects. Am J Med. 1984 May 15;76(5A):215–223. doi: 10.1016/0002-9343(84)90267-5. [DOI] [PubMed] [Google Scholar]
  12. Morikawa Y. Comparative pharmacokinetics of ampicillin and carbenicillin in the cerebrospinal fluid of rabbits with staphylococcal meningitis with reference to half-lives and areas under the curve. Jpn J Antibiot. 1981 Feb;34(2):211–218. [PubMed] [Google Scholar]
  13. Sande M. A. Antibiotic therapy of bacterial meningitis: lessons we've learned. Am J Med. 1981 Oct;71(4):507–510. doi: 10.1016/0002-9343(81)90191-1. [DOI] [PubMed] [Google Scholar]
  14. Täuber M. G., Sande M. A. Principles in the treatment of bacterial meningitis. Am J Med. 1984 May 15;76(5A):224–230. doi: 10.1016/0002-9343(84)90268-7. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES